Active for Dysautonomia

Hudson Medical, New York, NY
Dysautonomia+15 More Conditionsstellate ganglion block with 0.5% bupivacaine - Drug
18 - 100
All Sexes

Study Summary

This trial will assess if a nerve block can help reduce symptoms of long COVID.

Eligible Conditions
  • Dysautonomia
  • Dysautonomia Orthostatic Hypotension Syndrome
  • Post-COVID Syndrome
  • Long COVID
  • COVID-19 Recurrence
  • COVID-19
  • Post-Acute COVID-19 Syndrome
  • Post-Acute COVID-19 Infection
  • Long COVID Syndrome

Treatment Effectiveness

Study Objectives

8 Primary · 1 Secondary · Reporting Duration: 1 month

1 month
Ability to participate in social roles and activities status
Autonomic Symptoms: COMPASS-31 Score
Pain interference
Patient-Reported Outcomes: PROMIS-29 Score
Physical function
Sleep disturbance

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Active · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: stellate ganglion block with 0.5% bupivacaine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 month

Who is running the clinical trial?

Megan NicklayLead Sponsor
Jonathann Kuo, MDLead Sponsor

Eligibility Criteria

Age 18 - 100 · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have symptoms of COVID-19 that last for at least four weeks.

Frequently Asked Questions

Has the Active compound been verified by the FDA?

"Since this is a preliminary phase 1 trial, the safety of Active was estimated to be at level one due to limited data on their efficacy and security." - Anonymous Online Contributor

Unverified Answer

Are there any unfilled slots available in this research project?

"Affirmative. Per, this research initiative is actively accepting new participants. It was initially launched on December 1st 2022 and most recently amended on the same date, with a target of 20 patients at one single medical centre." - Anonymous Online Contributor

Unverified Answer

Do I satisfy the qualifications to enroll in this clinical experiment?

"This clinical trial seeks 20 individuals, ranging between 18 to 100 years of age, who are suffering from dysautonomia. Qualifying patients must have had a confirmed COVID-19 diagnosis by RT-PCR or equivalent testing and display lingering symptoms four weeks after the start of the infection. The COMPASS-31 is used to quantify autonomic symptom domains such as Orthostatic Intolerance and Vasomotor Alterations while PROMIS-29 measures patient reported pain interference or intensity." - Anonymous Online Contributor

Unverified Answer

Does this research permit elderly participants?

"The most recent review of the inclusion criteria specifies that patients must fall between 18-100 years old in order to participate. Separately, there are 947 separate clinical trials designed for minors and 3088 specifically tailored towards seniors." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.